Glenmark Pharma Q3 profit rises 16%, SAIL exceeds estimates
pre-market1 source ↓written by the desknot a recommendation
- in profit
- 16% increase
Glenmark Pharma reported a 16% increase in profit for Q3, reflecting strong operational performance. Meanwhile, SAIL's profit more than doubled, surpassing market estimates, indicating robust demand and cost management. These results come ahead of the Union Budget, potentially influencing market sentiment and trading strategies. 📈
Key Points:
• Glenmark Pharma's profit growth
• SAIL's profit more than doubles
• Earnings season impacts market dynamics
Not investment advice. For informational purposes only.